June 9 (UPI) A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous positive ...

But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness ...

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the country -- although patients appear more ready for the shift than the ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive ... when it comes to treatment for sleep apnea in those with obesity, a new study reports.

The researchers found that, for the treatment of comorbid obesity and obstructive sleep apnea, patients leaned toward tirzepatide while providers favored CPAP.

Dr. Cissy Kityo Mutuluuza is a physician, epidemiologist, medical researcher, and the executive director of the Joint ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main ... obstructive sleep apnoea, or cardiovascular disease, but without diabetes.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... obstructive sleep apnoea, or cardiovascular disease, but who did not have diabetes.

Smoky air often has obvious short-term health effects like coughing and sore throat, but it can also have long-term impacts ...

Communities across Asia's Himalayan Hindu Kush region face heightened disaster risks this monsoon season with temperatures ...

Consumer prices were only slightly affected by President Donald Trump’s tariffs in May, according to new numbers from the U.S. Bureau of Labor Statistics.